Objective. To analyse the distribution of predisposing DQ3 (DQB1*03(*04)uDQA1*03) and DQ5 (DQB1*0501uDQA1*01), shared epitope encoding and protective DRB1 alleles in patients with early rheumatoid arthritis (RA) and undifferentiated arthritis (UA).
A correlation exists between predisposition to RA and certain HLA-DQ3-DR4 and DQ5-DR1uDR10 haplotypes. The DRB1 alleles found in these haplotypes encode similar amino acid sequences in their third hypervariable region (3HVR), and this observation has been the basis of the shared epitope (SE) hypothesis w1x. In this model, the 3HVR motifs QKRAA, QRRAA and RRRAA of the DRB1*0101, *0102, *0401, *0404, *0405, *0408 and *1001 molecules constitute the molecular support for predisposition to RA. However, this model cannot explain, for instance, the differential associations of HLA-DR1 and -DR4 haplotypes in RA that have been described in many studies w2± 4x.
After a series of investigations in a mouse model of collagen-induced arthritis, which shows numerous similarities with RA, we have proposed a new hypothesis about the association between RA and the human leukocyte antigen (HLA) system w5, 6x. In this model, the predisposing alleles are DQ3 (DQB1*03uDQA1*03, and DQB1*04uDQA1*03 but not DQB1*03uDQA1*05) and DQ5 (DQB1*0501uDQA1*0101 and DQB1*0501u DQA1*0104), which are in linkage disequilibrium with DR4uDR9 and DR1uDR10 respectively. Meanwhile, DRB1 alleles encoding the peptide motif DERAA in their 3HVR region modulate this DQ-mediated predisposition. Recently, we have demonstrated the value of this model in a cross-sectional study analysing two groups of RA patients and controls w7x. The major conclusions of this analysis were that DQ3 homozygosity conferred the highest risk of developing RA while DERAA encoding DRB1 alleles provided dominant protection in DQ5-positive individuals.
In this model, the DERAA motif of the protective DRB1 proteins is part of an antigenic determinant binding DQ3 and DQ5 molecules. Recently, Das et al. w8x have shown that administration of such a peptide, derived from the DRB1*0402 chain, could in¯uence the course of collagen-induced arthritis in mice transgenic for a subtype of HLA-DQ3, DQB1*0302uDQA1*0301. A role for MHC peptides in immunoregulation is supported by the fact that a major fraction of natural ligands eluted from MHC class II molecules is constituted of MHC peptides themselves w9x. Moreover, MHC class II peptides can inhibit allorecognition in vitro w10, 11x.
Most studies on the role of HLA in RA have been cross-sectional. However, prospective studies involving patients with early manifestations are necessary to better evaluate the contribution of genetic polymorphisms to RA. Only a few publications have reported such analysis. Speci®cally, three groups w12±16x have looked at the distributions of HLA-DRB1 alleles using highresolution DNA typing in early arthritic patients, including patients not ful®lling the criteria for RA w17x. In these studies, the existence of possible protective alleles was not investigated. In the present study, we describe the ®rst extensive analysis of the distribution of DQB1, DQA1 and protective DRB1 alleles in a large group of patients with early arthritis.
Methods

Patients
In 1993, a special Early Arthritis Clinic (EAC) was started at the Department of Rheumatology of the Leiden University Medical Centre, the only centre for rheumatology in a health-care region of more than 300 000 inhabitants. Its protocol was designed as a population-based study of arthritic patients. To this end, patients enrolled in this programme were required to have arthritis of at least one joint diagnosed by a rheumatologist in the department with a duration of symptoms of less than 2 yr. Patients with trauma-related arthritis were excluded. The general practitioners in the area could refer the patients to the out-patient clinic if at least two of the following features were present: joint pain, joint swelling and reduction of joint mobility. The patients could be seen at the EAC within 1 week. For every patient, routine diagnostic laboratory screening was performed w18x. On entering the study and yearly thereafter, a 54-joint count of swollen joints was obtained. The metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints of each hand and the metatarsophalangeal joints of the foot were considered a single unit, so that a maximum of 22 swollen joints was measured. Diagnoses were made according to international classi®cation criteria after 2 weeks, and were revised after 3 months and yearly thereafter if necessary w18x. Patients who could not be diagnosed with the available criteria were referred to as undifferentiated (UA). Five hundred and ®fty-two HLA-DQ and -DR typed consecutive EAC patients completed 1 yr of follow-up. Three hundred and six Dutch cadaveric organ donors were used as HLA-DR and -DQ controls.
HLA typing DNA isolation, DRB1 typing and subtyping and DQB1 typing were performed as described previously w19x. Patients and controls were sorted according to their DQ-DR phenotypes, i.e. one or two copies of DQ3, one or two copies of DQ5 and the presence or absence of a protective DERAA encoding DRB1 allele. Accordingly, they were divided into eight groups (Table 1) . Patients and controls were also sorted according to the SE hypothesis: one or two copies of SE-positive DR4 and one or two copies of the DR1u10 alleles.
Statistics
To compare RA and undifferentiated arthritis patients with controls, odds ratios (OR) with 95% con®dence intervals (CI) were calculated as described previously w7x. An arbitrary ratio of 1 was given to the DQxux or DRxux group when appropriate. Frequencies were compared between groups using the x 2 test with Yates' correction. For disease severity, the medians in the different groups of patients were compared using the Mann±Whitney U-test.
Results
Among the 552 HLA-typed patients that had been enrolled in the EAC and completed the 1-yr follow-up, 195 patients were diagnosed as having de®nite RA according to the 1987 ACR criteria w17x and 160 patients remained undifferentiated.
We ®rst looked at the frequencies of the eight HLA phenotypes as de®ned in Table 1 in RA patients vs controls (Fig. 1a) . No signi®cant differences in the duration of symptoms before entering the EAC were observed among the eight different HLA groups (data not shown). To calculate the OR, an arbitrary value of 1 was given to the ratio of the number of patients with the phenotype DQxux divided by the number of controls with the same phenotype. A large proportion of DQ3ux patients carried a DRB1*0401 allele (36 out of 58). The remaining 22 patients carried DRB1*0403(06u07), *0404, *0405, *0408 or *0901. Most of the DQ5ux patients were DRB1*0101-positive (26 out of 32). Both DQ3ux and DQ5ux individuals were weakly, but signi®-cantly, predisposed to RA (OR = 3.04 and 2.56, respectively; Fig. 1a ). Similar analyses were performed using the SE model but still taking into account the protective effect of DERAA encoding DRB1 alleles. In this case, an arbitrary value of 1 was given to DRxux individuals. As shown in Fig. 1b , DR4ux individuals tended to be more predisposed to RA than DQ3ux individuals (OR = 4.07 vs 3.04).
DQ5u5 and DQ3u5 individuals tended to be more predisposed to RA (OR = 4.48 and OR = 4.97, respectively) than DQ3ux and DQ5ux individuals. Only DQ3u3 homozygosity displayed a signi®cant additive effect (OR = 20.00). Six of these DQ3u3 homozygotes were DRB1*0401u0401 homozygotes, two were DRB1*0404(8)u*0404(8) homozygotes and eight were DRB1*0401u*0404(8) heterozygotes. Interestingly, nine of them carried a single SE encoding allele, ®ve along with a DRB1*0403(06u07) allele and four along with a DRB1*0901 allele. Therefore, DQ3u3 homozygosity predisposed to RA more than DR4u4 homozygosity (OR = 20.00 vs 11.00; Fig. 1a and b) . As already reported using a smaller group of patients w19x, DERAA provided dominant protection among DQ5-positive (or DR1 anduor DR10-positive) (Fig. 1a and b) but not DQ3-positive individuals (OR = 0.18 vs 2.84). In most cases, protection was conferred by either DRB1*1301 or *1302, two common alleles in the Dutch population.
We then performed the same analyses using the 160 patients with UA ( Fig. 1c and d) . In contrast to the observations described above, the frequencies of genotypes DQ3u5 and DQ5u5 were not increased in this group. There was an excess of DQ3u3 homozygotes, but to a far lesser extent than in the group of RA patients (OR = 3.69 in UA vs 20.00 in RA patients). All six DQ3u3 UA patients carried two copies of SE-positive DRB1 alleles. Interestingly, DQ5ux, but not DQ3ux, individuals were signi®cantly predisposed to this relatively mild disease (OR = 2.15 vs 1.25; Table 2 ). Similarly, the numbers of DR1ux and DR10ux individuals were signi®cantly increased in the UA group (OR = 1.90; Fig. 1b) . In the EAC population, DQ5ux patients were signi®cantly more predisposed to UA than DQ3ux patients (OR = 2.04, 95% CI 1.07±3.92). DQ3uDERAA individuals tended to be found more often in this group than DQ3ux individuals (OR = 2.18 vs 1.25).
Rheumatoid factor (RF) positivity and the existence of polyarthritis are two important criteria for the early diagnosis of RA, because at this stage only a few patients have nodules anduor erosive disease. For this reason, we looked at RF positivity and the number of swollen joints at the ®rst hospital visit in the eight groups of HLA-typed patients (Table 2) . Patients with two doses of predisposing alleles (DQ3u3, DQ3u5, DQ5u5) were more frequently RF-positive (65%) than patients with one dose (DQ3ux and DQ5ux: 41%) (OR = 2.71, 95% CI 1.40±5.30). These heterozygous patients were more often RF-positive than patients with no predisposing HLA phenotypes (DQxux: 26%) (OR = 1.94, 95% CI 1.11±3.41) and patients with strong protection (DQ5uDERAA: 11%, only one patient out of nine).
On the basis of the results presented in Fig. 1 , we speci®cally looked at the differences in the number of swollen joints at the ®rst hospital visit between DQ3ux and DQ5ux individuals, along with the effect of the protective DERAA encoding DRB1 alleles. When RA and UA patients were pooled, DQ3 was found to be signi®cantly associated with a higher number of swollen joints than DQ5 (DQ3ux vs DQ5ux; P = 0.003). If DRB1*0401ux patients were discarded, the remaining DQ3ux patients still had a signi®cantly higher number of swollen joints at the ®rst hospital visit than the DQ5ux patients (P = 0.019). DERAA encoding DRB1 alleles were signi®cantly associated with a lower number of swollen joints among DQ3-positive individuals (P = 0.038). As expected, RA patients had a higher swollen joint count than UA patients (median 6.0 vs 2.0). In the group of RA patients, DQ3uDERAA individuals tended to have a lower count of swollen joints than DQ3ux individuals (median 4.5 vs 6.0), no DQ3uDERAA patients having more than seven swollen joints at the ®rst hospital visit. In the group of UA patients, DQ5ux individuals had a signi®cantly lower number of swollen joints than DQ3ux patients (P = 0.017). In this group, DQ3uDERAA patients also tended to have a lower joint count than DQ3ux patients. Therefore, it may be concluded that the relative associations of DQ5ux and DQ3uDERAA with UA correlate with lower disease activity at the ®rst hospital visit.
Discussion
Looking at the distributions of HLA-DQ and -DR alleles in patients with early signs of arthritis, we have demonstrated (i) the distinct contributions of the DQ3-DR4uDR9 and DQ5-DR1uDR10 haplotypes to early RA and UA, and (ii) the protective effect of DERAA encoding DRB1 alleles on disease susceptibility in DQ5-positive individuals and early disease activity in DQ3-positive individuals. We have shown that, at early stage of disease, HLA class II phenotypes can already separate patients with distinct predisposition and disease activity, e.g. DQ3ux vs DQ5ux or DQ3ux vs DQ3uDERAA. This suggests that a signi®c-ant fraction of UA patients (DQ5ux, DQ5uDERAA) represent a subgroup of individuals who will rarely ful®l the ACR criteria for RA or who will have a slowly progressive form of the disease (DQ3uDERAA). Indeed, DQ5ux and especially DQ5uDERAA individuals were not found to be predisposed to RA in a previous crosssectional study w7x. Furthermore, we have shown that DQ3-positive patients already have more active disease by the time they reach an out-patient clinic and are predisposed to RA.
Until now, the association of DR10 with RA has been described mostly in populations, such as Southern Europeans, in whom this allele is not as rare as it is elsewhere w1x. In the present study, we observed that, in spite of the low frequency of DR10 in the Dutch population (1%; only two individuals in the control group), this allele was weakly associated with RA (2%; four cases in the DQ5ux group) but was signi®c-antly associated with UA (5%, eight cases in the DQ5ux group; OR = 9.70, 95% CI 1.84±68.04). Therefore, the association of DQ5 with UA is independent of its linkage with DR1 or DR10.
The SE hypothesis cannot explain the dichotomy between DQ3-DR4 and DQ5-DR1u10, and accounts at best for the distinct roles of the DRB1*04 alleles in RA w4, 20x. Others have already reported differences in RA association among SE encoding DRB1*04 alleles w2, 12, 14, 21x. In our study, DQ3u3 homozygous individuals are more predisposed to RA than SE-positive DR4u4 individuals and homozygous DRB1*0401u0401 or heterozygous DRB1*0401u0404 individuals. We believe that DRB1*0401 has a special role in disease severity. However, this effect is probably better seen among patients with longstanding disease.
In the present study, 36% (nine out of 25) of high-risk DQ3u3 RA patients carried a SE-negative DRB1*0403, *0406, *0407 or *0901 allele. These individuals, who are strongly predisposed to RA, are not included in the highest risk group according to the SE model (DR4u4). The association of DRB1*0901 with RA has been described in some populations w22, 23x. Recently, Wakitani et al. w24x found that DRB1*0901 homozygotes were predisposed to RA in Japan. Although this is dif®cult to con®rm in Western countries due to the low frequency of the DRB1*0901 allele, we believe that the DQ3u3 genotype (DQB1*0303u*0303) of these DRB1*0901 homozygotes explains this association.
It is generally accepted that the role of HLA polymorphism in autoimmunity is to modulate the presentation of self-peptides to autoreactive T cells w25x. Thomas and Lipsky w26x have suggested that dendritic cells in®ltrating the joints play an essential role in initiating RA. This model is supported by the fact that dendritic cells present self-peptides, including self-MHC peptides, very ef®ciently w27x. However, we propose that dendritic cells in®ltrating the joints can also present selfpeptides in order to protect against RA. This mechanism should operate at an early stage of RA. Consistent with this model, we have shown that HLA acts very early in the disease process, at least before patients have reached an out-patient clinic. If the role of HLA were simply to present arthritogenic peptides to disease-eliciting T cells, there should not be a gene dose effect but rather a dominant mode of inheritance w28x. The gene dose effect of DQ3 on RA susceptibility suggests that DQ3-DR4uDR9 haplotypes encode impaired immunoregulation acting at an early stage of disease. Conversely, the association of DQ5 with this dysregulation is weaker and can be overcome by protective DERAA encoding DRB1 alleles. Many observations, starting with the lack of identi®ed autoantigens in RA, support a model in which HLA acts not only on susceptibility but also on protection w28x.
